| Rebif (human IFN-β-1a) / EMD Serono |
2004-004903-39: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. |
|
|
| Ongoing | 4 | 60 | Europe | Mitoxantrone, Glatiramer Acetate, Interferon Beta 1a, , Injection*, Mitoxantrone, Copaxone, Rebif 44 | The Walton Centre for Neurology and Neurosurgery | Early, active relapsing remitting Multiple Sclerosis (RRMS) | | | | |
NCT00367484 / 2004-000337-12: Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis |
|
|
| Completed | 4 | 460 | Europe | Rebif® (clone 484-39), Recombinant-human interferon beta-1a, r-hIFN Beta-1a | Merck KGaA, Darmstadt, Germany | Relapsing Remitting Multiple Sclerosis | 01/06 | 01/06 | | |
2006-000606-23: ?Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase Estudio post-autorización de seguridad para determinar la posible asociación entre el perfil de seguridad de interferón beta-1a y el índice de masa corporal o los marcadores farmacodinámicos durante la fase de escalado de dosis. |
|
|
| Ongoing | 4 | 100 | Europe | Interferon-beta-1a, Solution for injection, Rebif 22 y 44 mcg | Merck, S.L., Merck, S.L. | Not applicalbe Esclerosis múltiple remitente recurrente, Not applicable Esclerosis múltiple remitente recurrente, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT00078338: Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis |
|
|
| Completed | 4 | 764 | US, Europe, RoW | Rebif®, Recombinant interferon beta-1a, Copaxone®, Glatiramer acetate | EMD Serono, Pfizer | Relapsing-remitting Multiple Sclerosis | 11/06 | 11/06 | | |
NCT00202995: Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS |
|
|
| Terminated | 4 | 91 | US | Glatiramer Acetate, Betaseron, Rebif | Teva Branded Pharmaceutical Products R&D, Inc. | Relapsing Remitting Multiple Sclerosis | 10/07 | 10/07 | | |
NCT00317941: Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif |
|
|
| Completed | 4 | 220 | Europe | Betaferon/Betaseron, Rebif | Bayer | Relapsing-remitting Multiple Sclerosis | 04/08 | 04/08 | | |
REMAIN, NCT01142466: A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone |
|
|
| Completed | 4 | 30 | Europe | Interferon beta-1a (Rebif), Rebif | Merck KGaA, Darmstadt, Germany, Gesellschaft für Therapieforschung mbH | Multiple Sclerosis, Relapsing-Remitting | 12/09 | 01/10 | | |
SEPTIME, NCT01201343: Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients |
|
|
| Completed | 4 | 79 | Europe | Interferon beta-1a, Rebif | Merck KGaA, Darmstadt, Germany, Merck Serono S.A.S, France | Multiple Sclerosis, Relapsing, Remitting | 07/10 | 07/10 | | |
| Completed | 4 | 324 | US | Blood sampling | EMD Serono | Relapsing Multiple Sclerosis | 11/10 | 11/10 | | |
NCT01085318: Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial |
|
|
| Completed | 4 | 38 | US | Rebif | EMD Serono | Multiple Sclerosis | 02/12 | 03/12 | | |
|
|
|
|
|
|
|
EPOC, NCT01216072: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis |
|
|
| Completed | 4 | 1053 | US, Canada | Fingolimod, GILENYA™, Standard MS DMTs, Avonex®,, Copaxone®,, Rebif®,, Betaseron®,, Extavia® | Novartis Pharmaceuticals | Relapsing Forms of Multiple Sclerosis | 08/12 | 08/12 | | |
|
|
|
|
EPOC, NCT01534182: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg |
|
|
| Completed | 4 | 298 | RoW | Fingolimod, Gilenya, Interferon beta - 1a (IFN), Rebif, Glatiramer acetate (GA), Copaxone | Novartis Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 06/13 | 06/13 | | |
|
|
NCT00101959: Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects |
|
|
| Withdrawn | 4 | 0 | US | Rebif | EMD Serono | Relapsing-Remitting Multiple Sclerosis | | | | |
| Completed | 4 | 61 | Europe | Fingolimod, GILENYA™, Standard MS DMT, Avonex®,, Copaxone®,, Rebif®,, Betaferon®,, Extavia® | Novartis Pharmaceuticals | Relapsing Remitting Multiple Sclerosis | 06/14 | 06/14 | | |
2011-001956-12: Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis |
|
|
| Completed | 4 | 85 | Europe | Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia®, EU/1/97/033/002, EU/1/95/003/005-010, EU/1/98/063/001-003, EU/1/98/063/004-006, EU/1/08/454/001-002, EU/1/08/454/005-007, Injection, Avonex®, Betaferon®, Rebif 22®, Rebif 44®, Extavia® | University Hospital Motol | To correlate bioactivity of IFNβ reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNβ depending on NAbs status NAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested., Biological efficacy of IFNβ treatment in patiens with multiple sclerosis will be tested with the MxA protein,which will be detected in the blood. | | | | |
OUCH, NCT01834586: Anesthetic Topical Adhesive (Syneraâ„¢) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications |
|
|
| Completed | 4 | 30 | US | Anesthetic Topical Adhesive Synera, Synera | Brown, Theodore R., M.D., MPH | Multiple Sclerosis | 03/15 | 03/15 | | |
| Terminated | 4 | 1 | US | Rebif®, interferon-beta-1a | EMD Serono | Multiple Sclerosis | 04/15 | 04/15 | | |
2005-001026-89: Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone |
|
|
| Completed | 4 | 96 | Europe | Rebif 8,8 µg, Rebif 22µg, Rebif 44 µg, Rebif, Rebif | Serono GmbH | Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses | | 01/10 | | |
2005-001008-37: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy |
|
|
| Ongoing | 4 | 100 | Europe | Rebif®, Not applicable, Rebif®, Rebif® | Sahlgrenska University Hospital | Multiple sclerosis | | | | |
2007-004937-41: Etude du lien entre les marqueurs biologiques, la fatigue et les troubles cognitifs au cours de la sclérose en plaques de diagnostic récent et traitée par Interféron Bêta 1a SC (Rebif 44) |
|
|
| Ongoing | 4 | 40 | Europe | REBIF, REBIF, REBIF | Centre Hospitalier de Nancy | SLEROSE EN PLAQUE | | | | |
2009-013333-24: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) |
|
|
| Completed | 4 | 120 | Europe | REBIF, REBIF | MERCK SERONO SPA | RELAPSING MULTIPLE SCLEROSIS | | | | |
2011-003570-89: The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS Het effect van interferon beta-1a behandeling op het aanpassingsvermogen van de hersenen bij patienten met MS |
|
|
| Ongoing | 4 | 100 | Europe | Rebif, Rebif | VU University Medical Center, Merck Serono | Multiple sclerosis Multiple sclerose | | | | |
| Ongoing | 4 | 60 | Europe | beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada | Turku University Hospital, Novartis Pharma | Multiple sclerosis MS-tauti | | | | |
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann |
|
|
| Ongoing | 4 | 50 | Europe | Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia | Medizinische Universität Innsbruck, ABIRISK | Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose | | | | |
NCT02019550: Rebif® Rebidose® Versus Rebiject II® Ease-of-Use |
|
|
| Completed | 4 | 97 | US | Rebif Rebidose, Rebiject II | EMD Serono | Multiple Sclerosis, Relapsing-Remitting | 01/16 | 01/16 | | |
RebiQoL, NCT01791244: A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device |
|
|
| Completed | 4 | 93 | Europe | Rebif® | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 02/16 | 02/16 | | |
| Completed | 4 | 200 | Europe | Rebif® | Merck KGaA, Darmstadt, Germany | Multiple Sclerosis, Relapsing-Remitting | 04/16 | 04/16 | | |
| Completed | 4 | 106 | Europe | Rebif, Interferon beta-1a | Merck KGaA, Darmstadt, Germany, Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany | Relapsing Multiple Sclerosis, Clinically Isolated Syndrome | 08/16 | 08/16 | | |
| Withdrawn | 4 | 0 | US | Interferon Beta, Rebif or Betaseron/Betaferon, BIIB017 (Peginterferon beta-1a), PEGylated interferon beta-1a (IFN β-1a) | Biogen | Relapsing Multiple Sclerosis | 02/17 | 03/18 | | |
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros. |
|
|
| Ongoing | 4 | 150 | Europe | Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio | Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet | Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10] | | | | |
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders" |
|
|
| Ongoing | 4 | 300 | Europe | Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency | Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 4 | 80 | Europe | peginterferon beta-1a, PLEGRIDY, BIIB017, interferon beta-1a, Rebif, interferon beta-1b, Betaferon, Extavia | Biogen | Relapsing Remitting Multiple Sclerosis | 10/20 | 10/20 | | |
| Active, not recruiting | 4 | 800 | Europe, US | Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod) | The Cleveland Clinic, University of Nottingham | Multiple Sclerosis, Relapsing-Remitting | 04/30 | 09/30 | | |
